Medical Product Technologies
One of the major issue in cannabis use for medical purpose is the precise dosing and delivery technology. As a scientific team, Apotheca are taking on to that challenge; with our in-house engineering and cannabis science expertise, we have developed various delivery and device technologies which will have far-reaching impact on how to effectively deliver precise dose of cannabis compounds to patients. Apotheca’s canna-pipeline of products includes, transdermal, sublingual, and nasal targeted delivery of cannabinoids with novel formulation technologizes.
Apotheca has developed three core platform technologies; CannaRAPID™, CannaNASAL™, and CannaDERME™ focused on precise dosing and controlled release of cannabinoid compounds for patients. The technologies and formulations of these technologies are completed a d several application areas and medical products based on these core-technologies are being developed for various indications.
CannaRAPID™: Proprietary sublingual delivery technologies using orally disintegrating tablet technology.
There are several inherent benefits of sublingual delivery of drugs such as fast absorption, avoidance of unwanted liver and gut microbiota metabolism on active drug. Further, as medical cannabis is going to be on mainstream medicine, there is an urgent need for a new dosage and delivery form that can improve patient compliance. Common complaints about the difficulty in swallowing tablets in the order of frequency of complaints are size, surface, form, and taste of tablets are common in various patient groups. Geriatric and pediatric patients and traveling patients who may not have ready access to water are most in need of easy swallowing dosage forms.
Almost 50% of people suffer from some form of dysphagia, or difficulty in swallowing” said Bobban Subhadra, M.S., Ph.D, CEO of Apotheca Earth. “Solid dosage forms that can be dissolved or suspended with water in the mouth for easy swallowing are highly desirable for the pediatric and geriatric population, as well as other patients who prefer the convenience of readily administered dosage forms and that is reason why we come up with CannaRAPID” he added.
Apotheca Biosciences’ sublingual product, CannaRAPID is a sugar-free Orally Disintegrating Tablet to deliver precise dose cannabinoids to neural tissues in a matter of seconds. The formulation is optimized with nanotechnology and tissue permeation enhancing molecules for faster absorption. Apotheca Biosciences pairing up with clinical organizations and various clinical practitioners for conducting clinical studies using CannaRAPID for various indications such as stress and anxiety relief, cognitive focus, various kinds of pain, migraines etc
Opioid Addiction in US CannaRAPID™ might be the answer for treating opioid addiction
United States is in the middle of an unprecedented opioid epidemic; Since 1999, the rate of overdose deaths involving opioids nearly quadrupled, and over 165,000 people have died from prescription opioid overdoses. Prescription pain medication deaths remain far too high, and in 2014, the most recent year on record, there was a sharp increase in heroin-involved deaths and an increase in deaths involving synthetic opioids such as fentanyl. Prevention, treatment, and research to rapidly tackle and reverse opioid overdoses are critical to fighting this epidemic.
Early data coming out of states where marijuana laws have been passed suggest that even as conventionally used, marijuana may be playing a role in offsetting the opioid addiction epidemic. Studies have shown that phytocannabinoids like cannabidiol have promising results in opioid withdrawal symptoms and heroin-seeking behavior.
Our studies have shown that cannabidiol can have promising improvements in opioid withdrawal symptoms by attenuating the rewarding effects of opioids. There is at least partial evidence that cannabinoid compounds can relieve from depression. Apotheca Biosciences is partnering with opioid addiction centers and clinical practitioners to conduct studies on the use of CannaRAPID for opioid addiction.
“Data is showing that on an average day in US about 78 people die from an opioid-related overdose, most of the ones died belongs to the younger population” said Bobban Subhadra, M.S., Ph.D, CEO at Apotheca Earth. “This is a serious epidemic that need to be dealt with a high level of urgency; we are talking about teens who are the future of our nation dying in high numbers on our streets. That is the reason, why we at Apotheca Earth, wanted to seriously investing in the application of our CannaRAPID as a possible intervention for opioid addiction. Even if we can save one young life with our CannaRAPID sublingual technology, we will take it as a enormous success” he added.
Apotheca Biosciences sublingual product, CannaRAPID is a sugar-free Orally Disintegrating Tablet to deliver precise dose cannabinoids to neural tissues in a matter of seconds. The formulation is optimized with nanotechnology and tissue permeation enhancing molecules for faster absorption. There are several inherent benefits of sublingual delivery of drugs such as fast absorption, avoidance of unwanted liver and gut microbiota metabolism of active drug. Further, as medical cannabis is going to be on mainstream medicine, there is an urgent need for a new dosage and delivery form that can improve patient compliance.
Apotheca Biosciences is pairing up with clinical organizations and various clinical practitioners for conducting clinical studies on the use of CannaRAPID as an adjunct therapy for opioid addiction. Our preliminary studies show that opioid doses can be significantly reduced by the use of CannaRAPID. It has two synergistic benefits: CBD reduces opioid addiction signaling pathway by working in the brain addiction reward system while simultaneously helps to alleviate pain.
CannaDERME™ : Transdermal technology using nano-emulsion for fast absorption of cannabinoid compounds.
The CannaDERME has transcutaneous cannabinoid penetration technology coupled with nano-emulsion for sustained release of compounds for longer time. The formulation delivers therapeutic doses to target areas (e.g. brain stem, cuteneous sympathetic nervous system)for whole-body effect. Cutaneous neuromediators include classical neurotransmitters, such as the catecholamines and acetylcholine, which are released from the automatic nervous
system or cutaneous cells. Skin being the largest organ, it has the potential to permeate effective doses to specific target organs as well as to systemic circulation without first pass gut metabolism.
Apotheca Biosciences is partnering up with physician groups for conducting clinical studies using CannaDerme line for various indications (Chronic pain, Acne, Atopic Dermatitis).
CannaNASAL™ : Nasal delivery technology using liposomal nanoparticles